FibroGen is radically restructuring its business, laying off 75% of its U.S. staff and stopping investment in its lead candidate in response to the failure of two late-phase pancreatic cancer clinical trials. One year ago, FibroGen laid off 104... — read more
Cuts have started, brace for more
FibroGen cuts jobs as it weighs anemia dr-g's future in US FibroGen is cutting jobs and restructuring as it struggles to get an anemia pill back on track in the U.S. after a major regulatory... — read more